Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | SPOP | O43791 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3949605 | 1.00 | KDM4E (0.33) | KDM4EALDH1A1CYP3A4MAPTAPEX1 | |
| SCHEMBL8669676 | 0.85 | KDM4E (0.35) | KDM4EALDH1A1CYP3A4MAPTAPEX1 | |
| SCHEMBL10429508 | 0.82 | KDM4E (0.32) | KDM4EALDH1A1CYP3A4MAPTAPEX1 | |
| SCHEMBL11130790 | 0.81 | NR1I2 (0.32) | KDM4EALDH1A1CYP3A4MAPTAPEX1 | |
| SCHEMBL4048933 | 0.81 | KDM4E (0.30) | KDM4EALDH1A1CYP3A4MAPTAPEX1 | |
| SCHEMBL4048939 | 0.81 | KDM4E (0.30) | KDM4EALDH1A1CYP3A4MAPTAPEX1 | |
| SCHEMBL10429526 | 0.76 | NR1I2 (0.32) | NR1I2PGRPTGS2 | |
| SCHEMBL11497574 | 0.75 | KDM4E (0.40) | KDM4EALDH1A1CYP3A4MAPTAPEX1 | |
| SCHEMBL6731795 | 0.74 | — | — | |
| SCHEMBL3188369 | 0.74 | KDM4E (0.34) | KDM4EALDH1A1CYP3A4MAPTAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488724-B2 | 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors | SOUTHERN METHODIST UNIVERSITY FOUNDATION FOR RESEARCH (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1430060-B1 | 7-ALKYLIDENE-3-SUBSTITUTED-3-CEPHEM-4-CARBOXYLATES AS BETA-LACTAMASE INHIBITORS. | UNIV SOUTHERN METHODIST (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060074065-A1 | 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors | ALAMX LLC | 2006-04-06 | — | — | US | disclosed |
| US-6916801-B2 | 7-Alkylidene-3-substituted-3-cephem-4-carboxylates as β-lactamase inhibitors | ALAMX, LLC (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1430060-A2 | 7-ALKYLIDENE-3-SUBSTITUTED-3-CEPHEM-4-CARBOXYLATES AS BETA-LACTAMASE INHIBITORS. | ALAMX, L.L.C. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030092696-A1 | 7-Alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors | SOUTHERN METHODIST UNIVERSITY FOUNDATION FOR RESEARCH | 2003-05-15 | — | — | US | disclosed |
| WO-2003020732-A2 | 7-ALKYLIDENE-3-SUBSTITUTED-3-CEPHEM-4-CARBOXYLATES AS BETA-LACTAMASE INHIBITORS. | ALAMX, L.L.C. (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074065-A1 | 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors | CMBL, CES2, BCHE | KDM4E 123/4885ALDH1A1 212/4885CYP3A4 11/4885 |
| US-20030092696-A1 | 7-Alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors | CES1, SULT1E1, CES2 | KDM4E 122/4885ALDH1A1 80/4885CYP3A4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.